Cantù, Italy

Silvia Moiana

This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignees: Evultis Sa, Friulchem Spa. Active years: 2013-2015.


% Patents Active = 50.0

 

Average Co-Inventor Count = 2.4

ph-index = 1


Company Filing History:


Years Active: 2013-2015

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Silvia Moiana: Innovator in Pharmaceutical Processes

Introduction

Silvia Moiana is a prominent inventor based in Cantù, Italy. She has made significant contributions to the field of pharmaceuticals, particularly in the synthesis and preparation of various compounds. With a total of 2 patents, her work focuses on improving the quality and safety of pharmaceutical formulations.

Latest Patents

Silvia's latest patents include innovative processes for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin. The first patent details a process for the preparation of rifaximin, pseudo-crystalline rifaximin, and a new pseudo-crystalline form of rifaximin with fewer impurities. The second patent outlines a comprehensive process for producing non-genotoxic diacetylrhein (diacerein). This process involves transforming raw diacerein into a water-soluble salt, adsorbing the salt solution on a hydrophobic resin, and eliminating impurities to ensure the final product is suitable for pharmaceutical use.

Career Highlights

Throughout her career, Silvia has worked with notable companies such as Friulchem Spa and Evultis S.A. Her expertise in pharmaceutical processes has positioned her as a valuable asset in the industry.

Collaborations

Silvia has collaborated with professionals like Disma Mazzola and Germano Coppi, contributing to her innovative projects and enhancing her research capabilities.

Conclusion

Silvia Moiana's contributions to pharmaceutical innovations demonstrate her commitment to improving drug safety and efficacy. Her patents reflect her dedication to advancing the field and ensuring high-quality formulations for both human and veterinary use.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…